

The Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA HEALTH GROUP INC.

中國醫療集團有限公司

(Carrying on business in Hong Kong as “萬全醫療集團”)
(Formerly known as “Venturepharm Laboratories Limited”)
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 08225)

POSITIVE PROFIT ALERT

This announcement is made by China Health Group Inc. (the “**Company**”) together with its subsidiaries (altogether, the “**Group**”) pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”) and the Inside Information Provisions (as defined under the GEM Listing Rules) under Part XIVA of the *Securities and Futures Ordinance* (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform shareholders and potential investors of the Company that, according to the preliminary review of the unaudited consolidated management accounts of the Group and other information currently available to the Company, it is expected that the annual profit attributable to equity shareholders of the Company for the year ended 31 December 2017 will increase significantly by more than 13 times as compared with the year of 2016. The expected significant increase was mainly due to the increase in the revenue, gross profit margin and net profit margin recognized in the year of 2017.

The information set out in this announcement is only based on a preliminary assessment by the management of the Company based on the consolidated management accounts of the Company and other information currently available to the Company, which has not been fully reviewed by the Company’s auditors. The annual results for the year ended 31 December 2017 to be disclosed in the annual results announcement of the Company shall prevail.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
China Health Group Inc.
William Xia GUO
Chairman

Hong Kong, 19 March 2018

As at the date of this announcement, the Board comprises: (a) Executive Directors: William Xia GUO and Maria Xuemei SONG; (b) Non-Executive Director: Michael SU; (c) Independent Non-Executive Directors: Rui Qiu, Mark Gavin Lotter and Bin Hui Ni.

*This announcement, for which the directors of the Company (the “**Directors**”) collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*